Targeted radiation shows promise for Tough-to-Treat prostate cancer

NCT ID NCT05219500

Ongoing Disease control Sponsor: Fusion Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a drug called FPI-2265, which delivers targeted radiation directly to prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a form that has spread and no longer responds to hormone therapy. The study will measure how well the drug lowers PSA levels and monitor side effects in 115 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FPI-2265 (a targeted radiation therapy that seeks out prostate cancer cells)
What this could lead to: If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a mid-stage trial with only 115 participants, so results may not apply to everyone. The treatment involves radioactive material, which can cause side effects like dry mouth or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Excel Diagnostics and Nuclear Oncology Center

Houston, Texas, 77042, United States
XCancer Omaha/Urology Cancer Center

Omaha, Nebraska, 68130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.